About PATH EX
PATH EX is a Healthcare company based in Nashville (United States) founded in 2016 by Alex Wieseler and Sinead Miller. It operates as a developing blood-cleansing device to remove pathogens from circulating blood. PATH EX has raised $5 million across 6 funding rounds from investors including MedTech Innovator, MassChallenge and America’s Seed Fund. Its chief executive is Sinead Miller. PATH EX offers products and services including PATH EX Therapeutic and PATH EX Diagnostic. Its focus areas include Life Sciences, Infectious Diseases, Medical Devices and Therapeutics. Its competitors include Aethlon Medical, Cerus, Amferia, Ondine Biomedical and Z-App Kit and 4 more; 4 of its 9 listed competitors have raised funding.
Company details
PATH EX was founded in 2016 in Nashville, United States, with operations centered on medical device development in the biotechnology sector. An extracorporeal blood-cleansing device is being created to eliminate multi-drug resistant bacteria and endotoxins from blood circulation. Pre-clinical studies indicated a 95 bacteria reduction in a single pass. The companys work targets pathogen removal technologies for potential clinical applications.
- Total Equity Funding$5M (USD)
in 6 rounds
- Latest Funding Round$5M (USD), Series A
May 2025
- InvestorsMedTech Innovator
& 7 more
Products & Services of PATH EX
PATH EX offers a comprehensive portfolio of products and services, including PATH EX Therapeutic and PATH EX Diagnostic.
Device removes pathogens and endotoxins from blood for sepsis treatment.
Captures pathogens from blood for identification without culturing.
Funding Insights of PATH EX
PATH EX has successfully raised a total of $5M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $5 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5M
- Total Rounds 6
- Last Round Series A — $5M
- Investors Count 8
All 6 funding rounds of PATH EX with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2025 | $5M | Series A | – | IAG Capital Partners | |
| Sep 2021 | $25,000 | Grant | – | – | |
| Oct 2020 | $100,000 | Grant | – | – | |
| Jun 2018 | $909,999 | Grant | – | – | |
| Jul 2017 | $225,000 | Grant | – | – | |
| Jun 2017 | – | Seed | – | – |
8 investors in total: 8 institutional.
Investors in PATH EX
PATH EX has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include MedTech Innovator, MassChallenge and America’s Seed Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Acceleration of medical device, digital health, and diagnostic companies is facilitated worldwide. | – | medtechinnovator.org | - | |
Early-stage entrepreneurs are accelerated through MassChallenge's program. | – | masschallenge.org | Boston, United States | |
Venture capital fund backed by the US Government | – | seedfund.nsf.gov | Alexandria, United States | |
Early-stage investments are made in high-growth technology companies. | – | innovamemphis.com | Memphis, United States | |
Venture capital investments are provided by IAG Capital Partners. | – | iagcapitalpartners.com | Charleston, USA | |
Early-stage Life-Sciences & Offline focused VC firm funding companies in the US | – | tmcventurefund.com | Houston, United States | |
- | – | fitzgate.com | - | |
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States |
Investor details for PATH EX
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of PATH EX
2 people are tracked at PATH EX (2 in leadership).
| Name | Role | Group |
|---|---|---|
Alex Wieseler | Co-Founder & COO | Leadership |
Sinead Miller | Co-Founder & CEO | Leadership |
Complete people profiles for PATH EX
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of PATH EX
3 dated milestones of PATH EX across 9 years, from founding to its latest funding, stage changes and deals.
- Founded PATH EX is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $5.0M.
Competitors of PATH EX
PATH EX has 9 listed competitors in our database, 4 of them funded. They include Aethlon Medical, Cerus, Amferia, Ondine Biomedical and Z-App Kit, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aethlonmedical.com | 1999 | San Diego, United States | – | 14 | Hemopurification devices are developed to eliminate viruses and exosomes. | |
| cerus.com | 1991 | Concord, United States | – | 247 | Provider of pathogen inactivation technology for blood center or hospital blood bank | |
| amferia.com | 2018 | Gothenburg, Sweden | $3.45M | – | Anti-infective technology is developed using selective anti-bacterial polymers. | |
| ondinebio.com | 1999 | Vancouver, Canada | – | 49 | Anti-infective therapies are developed via light-activated Photodisinfection technology. | |
| zappkit.com | 2007 | Hafnarfjordur, Iceland | – | – | Provides frequency therapy through mobile app and hardware for user health support. | |
| laradasciences.com | 2006 | Salt Lake, United States | $2.63M | – | Head lice are removed by a network of certified professionals. | |
| 3oescientific.com | 2010 | Carmel, United States | $3.71M | – | Provider of smart solutions to manage pathogen infections | |
| toefx.com | 2016 | Hamilton, Canada | $30,000 | – | Treatments for toenail fungus are developed using photodynamic therapy. | |
| tcubeit.com | 2019 | Sejong, South Korea | – | – | T cell-based immuno-therapeutics for cancer and infectious diseases are developed. |
Detailed competitors of PATH EX
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
10 companies that operate in the same segment as PATH EX (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | 172 | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | 329 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Path Ex
Complete news archive for PATH EX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PATH EX
PATH EX was founded in 2016 and raised its 1st funding round 1 year after it was founded.
PATH EX is headquartered in Nashville, United States. It is registered at Nashville, Tennessee, United States.
Sinead Miller is the current CEO of PATH EX. They have also founded this company.
PATH EX is a funded company, having raised a total of $5M across 6 funding rounds to date.
PATH EX was founded in 2016 in Nashville, United States, with operations centered on medical device development in the biotechnology sector. An extracorporeal blood-cleansing device is being created to eliminate multi-drug resistant bacteria and endotoxins from blood circulation. Pre-clinical studies indicated a 95 bacteria reduction in a single pass. The companys work targets pathogen removal technologies for potential clinical applications.
PATH EX's top competitors include Cerus, Aethlon Medical and Amferia.
PATH EX offers PATH EX Therapeutic and PATH EX Diagnostic.
PATH EX has 8 investors. Key investors include MedTech Innovator, MassChallenge, America’s Seed Fund, Innova Memphis, and National Science Foundation.